

Edgar Filing: INCYTE GENOMICS INC - Form 424B3

INCYTE GENOMICS INC  
 Form 424B3  
 February 23, 2001

PROSPECTUS SUPPLEMENT  
 dated February 23, 2001  
 to Prospectus dated August 2, 2000

Filed Pursuant to Rule 424(b)(3)  
 Registration No. 333-36318

\$200,000,000

INCYTE GENOMICS, INC.

5.5% CONVERTIBLE SUBORDINATED NOTES DUE 2007  
 and  
 SHARES OF COMMON STOCK  
 ISSUABLE UPON CONVERSION OF THE NOTES

This prospectus supplement relates to the resale by the holders of 5.5% convertible subordinated notes due 2007 of Incyte Genomics, Inc. and the shares of common stock issuable upon conversion of the notes.

This prospectus supplement should be read in conjunction with the prospectus dated August 2, 2000, which is to be delivered with this prospectus supplement.

The information in the table appearing under the heading "Selling Securityholders" in the prospectus is supplemented and superseded in part by the information appearing in the table below:

Name	Principal Amount of Notes Beneficially Owned and Offered(1)	Common Stock Issuable Upon Conversion of the Notes(1) (2)	Common Stock Offered(1) (2)
LEXINGTON VANTAGE FUND LTD. ....	\$50,000	741	741

Investing in the notes and our common stock involves a high degree of risk. You should carefully read and consider the "Risk Factors" beginning on page 3 of the prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the prospectus. Any representation to the contrary is a criminal offense.

Prospectus Supplement dated February 23, 2001